Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 703.84

+1.5%

10:06 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

DewDiligence_on_SI

To: DewDiligence_on_SI who wrote (2409)	5/6/2018 10:24:17 PM
From: Miljenko Zuanic	1 Recommendation Read Replies (1) of 3559

KEYNOTE-598 clinicaltrials.gov KEYNOTE-006 clinicaltrials.gov Not the same, not at all. MRK is testing Pembro + Y against Pembro + placebo, hoping that trial will FAIL, and prove that Y dose not bring value to combo. Like MBY, REGN is looking for 2810 + Y against chemo (in wast majority NSCLC). So, what if trial does show benefit of adding Y to any 2810 combo? How they will prove that their own anti-CTLA4 work as well without NEW P3 (another 4 years of trial, for OS). How they will differentiate 2810 from Nivo in those combinations? For me this is promotion of the Y and Y + Nivo, and REGN/SNY are PAYING FOR IT! IMBECILES, that is my answer to them. IF they believe that anti-CTLA-4 have place in IO/IO combinations, bring your own candidate QUICKLY to P2 levels (define safe doses range) and start doing your own pivotal trials. Unless they already concluded that their own "Y" is at lower potency, so they need to redesign candidate and that take time.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next